• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Switzerland·Healthcare·GALE.SW
Share

Galenica AG Stocks

CHF 83.9Last Updated 27.08.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CHF 5.10B

CHF 83.9
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Galenica AG stands as a leading healthcare services company, serving both the Swiss market and international clients. Its operations are organized into two principal divisions: "Products & Care" and "Logistics & IT." The "Products & Care" division oversees an extensive network of 520 pharmacies, comprising 368 directly owned outlets and 152 partner-affiliated pharmacies, operating under the recognized brand names of Amavita, Sun Store, and Coop Vitality. Beyond retail pharmacy services, this segment also provides medication for patients receiving home-based treatment. It is also responsible for the introduction and distribution of a diverse portfolio of consumer health, pharmaceutical, and parapharmaceutical products, in addition to offering vital marketing and sales support to its collaborators within the healthcare sector. The "Logistics & IT" division specializes in offering a suite of pre-wholesale services tailored for pharmaceutical and healthcare enterprises. These services encompass essential functions such as secure storage, efficient distribution, and comprehensive debt collection. Furthermore, this segment provides various logistics and information technology solutions, including a master data system specifically developed for the healthcare industry. It actively creates advanced management solutions relevant to the healthcare market and publishes technical information on pharmaceutical products in both printed and electronic formats, alongside delivering complete management tools for pharmacies. Founded in 1927, Galenica AG maintains its headquarters in Bern, Switzerland.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of GALE.SW is 85.5 and suggests 3.91% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommenda

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.08.2026 23:34

"Worsha was seen as a hawk": The market sharply raised expectations for a rate hike in September

28.08.2026 21:40

"The Schrodinger's Cat Situation": Analysts Take Stock of Six Months of the U.S.-Iran War

28.08.2026 20:58

BioNTech and Roche have halted a cancer vaccine trial. What does this mean for the industry?

28.08.2026 19:14

The Fed "has a lot of work ahead" if inflation doesn't come down quickly — Warsh

28.08.2026 19:05

"The Main Focus for the Markets": What to Expect from the Fed Chair's Speech in Jackson Hole

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026